Last 48 quarters of trend data · Healthcare · Medical - Care Facilities
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Chemed Corporation's quarterly P/E stands at 19.5x, down 38.5% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 22.1% YoY to 15.9x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 23.12 | 19.47 | 19.52 | 25.10 | 34.10 | 31.65 | 22.00 | 29.93 | 29.17 | 37.85 | 24.78 | 26.35 | 38.58 |
| — | -38.5% | -11.3% | -16.1% | +16.9% | -16.4% | -11.2% | +13.6% | -24.4% | +0.8% | -19.8% | -8.7% | +44.7% | |
| P/S Ratio | 2.30 | 1.96 | 2.34 | 2.60 | 2.87 | 3.51 | 3.10 | 3.74 | 3.47 | 4.18 | 3.81 | 3.50 | 3.72 |
| — | -44.1% | -24.5% | -30.4% | -17.2% | -16.0% | -18.6% | +6.9% | -6.7% | +15.2% | +8.4% | +12.2% | +11.5% | |
| P/B Ratio | 6.26 | 6.09 | 6.11 | 6.04 | 5.93 | 7.69 | 7.10 | 7.33 | 6.85 | 8.32 | 8.06 | 7.75 | 8.66 |
| — | -20.8% | -13.9% | -17.6% | -13.4% | -7.6% | -11.9% | -5.4% | -20.8% | -9.9% | -16.2% | -14.9% | -16.4% | |
| P/FCF | 17.89 | 18.16 | 12.77 | 24.64 | 14.48 | 116.68 | 13.05 | 29.44 | 31.13 | 34.01 | 23.06 | 114.34 | 17.78 |
| — | -84.4% | -2.1% | -16.3% | -53.5% | +243.1% | -43.4% | -74.3% | +75.1% | -27.2% | -1.6% | +168.6% | -56.3% | |
| EV / EBITDA | 14.65 | 15.92 | 12.97 | 17.91 | 20.77 | 20.44 | 15.24 | 20.80 | 19.74 | 27.45 | 17.37 | 19.23 | 24.29 |
| — | -22.1% | -14.9% | -13.9% | +5.2% | -25.6% | -12.3% | +8.2% | -18.7% | +16.9% | -15.1% | +8.0% | +41.8% | |
| EV / EBIT | 17.45 | — | 14.32 | 19.05 | 24.48 | 23.58 | 16.38 | 22.11 | 21.74 | 28.50 | 19.02 | 20.98 | 28.91 |
| — | — | -12.6% | -13.8% | +12.6% | -17.3% | -13.9% | +5.4% | -24.8% | +0.7% | -18.6% | -4.1% | +37.0% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Chemed Corporation's operating margin was 12.9% in Q1 2026, down 2.9 pp QoQ and down 1.8 pp YoY.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.0% | — | 32.2% | 28.9% | 29.8% | 33.5% | 36.6% | 34.6% | 34.6% | 34.6% | 38.8% | 35.8% | 32.4% |
| — | — | -11.9% | -16.5% | -13.7% | -3.4% | -5.8% | -3.3% | +6.7% | +2.4% | +7.7% | +5.0% | -11.4% | |
| Operating Margin | 13.4% | 12.9% | 15.7% | 12.0% | 11.0% | 14.6% | 17.8% | 15.2% | 14.8% | 12.3% | 19.0% | 15.4% | 12.6% |
| — | -12.2% | -11.5% | -21.3% | -25.6% | +19.3% | -6.4% | -1.2% | +17.8% | -5.6% | +27.8% | +0.2% | -27.5% | |
| Net Margin | 10.5% | 10.1% | 12.0% | 10.3% | 8.5% | 11.1% | 14.1% | 12.5% | 11.9% | 11.0% | 15.4% | 13.3% | 9.6% |
| — | -9.1% | -14.9% | -17.8% | -28.7% | +0.5% | -8.2% | -5.9% | +23.4% | +14.2% | +35.2% | +22.9% | -22.9% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 25.3% | 7.3% | 7.5% | 5.6% | 4.4% | 6.2% | 7.7% | 6.2% | 5.9% | 5.7% | 8.5% | 7.6% | 5.8% |
| — | +16.3% | -2.7% | -9.0% | -25.6% | +9.9% | -9.4% | -18.4% | +1.8% | -12.0% | +3.6% | -6.0% | -40.7% | |
| ROA | 16.0% | 4.2% | 4.7% | 3.8% | 3.0% | 4.2% | 5.3% | 4.3% | 4.1% | 3.8% | 5.6% | 4.9% | 3.6% |
| — | -1.2% | -10.5% | -11.1% | -25.6% | +10.4% | -5.8% | -11.5% | +12.6% | +1.6% | +25.6% | +14.7% | -28.4% | |
| ROIC | 23.7% | 6.0% | 7.0% | 5.1% | 4.5% | 6.4% | 7.7% | 6.1% | 6.2% | 5.4% | 8.4% | 6.8% | 5.4% |
| — | -6.3% | -8.4% | -15.4% | -26.2% | +18.2% | -9.0% | -10.7% | +13.4% | -3.4% | +33.5% | +6.2% | -27.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Chemed Corporation's Debt/EBITDA ratio is 2.8x, up from 1.3x last quarter — at a moderate level that warrants monitoring. The current ratio has weakened 50.7% YoY to 0.85x, tightening the short-term liquidity position. Debt/Equity has risen for 4 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.16 | 0.28 | 0.16 | 0.13 | 0.12 | 0.12 | 0.13 | 0.12 | 0.12 | 0.12 | 0.14 | 0.13 | 0.15 |
| — | +127.6% | +25.5% | +9.8% | +0.2% | -0.6% | -10.1% | -10.9% | -18.1% | -34.4% | -54.7% | -60.6% | -60.9% | |
| Debt / EBITDA | 0.38 | 2.80 | 1.32 | 1.55 | 1.73 | 1.31 | 1.09 | 1.37 | 1.41 | 1.66 | 1.22 | 1.34 | 1.66 |
| — | +113.9% | +21.8% | +13.4% | +22.4% | -21.0% | -11.1% | +2.4% | -15.3% | -12.4% | -52.5% | -48.0% | -31.2% | |
| Current Ratio | 1.05 | 0.85 | 1.05 | 1.35 | 1.86 | 1.73 | 1.38 | 1.85 | 1.78 | 1.91 | 1.61 | 1.33 | 1.11 |
| — | -50.7% | -23.7% | -26.9% | +4.9% | -9.6% | -13.9% | +39.5% | +59.2% | +106.9% | +75.0% | +99.0% | +56.4% | |
| Quick Ratio | 1.03 | 0.83 | 1.03 | 1.33 | 1.83 | 1.70 | 1.35 | 1.81 | 1.73 | 1.88 | 1.57 | 1.29 | 1.08 |
| — | -51.2% | -24.0% | -27.0% | +5.4% | -9.2% | -13.6% | +41.2% | +61.2% | +111.4% | +77.5% | +103.4% | +59.4% | |
| Interest Coverage | 204.30 | 165.19 | 203.39 | 42.75 | 161.53 | 291.80 | 241.73 | 237.60 | 219.71 | 199.79 | 338.99 | 211.06 | 92.24 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying CHE stock.
Chemed Corporation's current P/E is 23.1x. The average P/E over the last 4 quarters is 24.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Chemed Corporation's current operating margin is 13.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Chemed Corporation's business trajectory between earnings reports.